Financial Times Reports On Controversy Over Cost Of New HCV Medication

Financial Times: Hepatitis C: Treated — at a price
“…The launch in recent weeks of sofosbuvir, the first of a series of new drugs for hepatitis C virus (HCV) set for regulatory approval, raises the prospect of curing and potentially eliminating a disease that levies a heavy global burden. … Yet in one of many parallels between HCV and HIV, sofosbuvir has sparked controversy over its high price…” (Jack, 1/27).